Protective Effect of Compound Formula Rehmannia against Neurotoxicity and Apoptosis Induced by α‐Syn in In Vivo and In Vitro Models of Parkinson’s Disease

Teng Long, Minchun Yang, Xiaoqing Jin, Qian Lu, Weijia Yang, Xuanxuan Ren, Qing QuEvidence-based 2020 · DOI

TL;DR

This study investigates Compound Formula Rehmannia (CFR), a traditional Chinese medicine, for its potential to protect against Parkinson's Disease (PD) by targeting alpha-synuclein (α-syn) toxicity. Researchers found that CFR significantly reduced neurotoxicity and apoptosis in both animal models and cell cultures of PD, suggesting it could be a promising therapeutic agent.

What Problem Does This Paper Address?

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons, leading to motor symptoms like tremors and rigidity. While current treatments like Levodopa can manage symptoms, they don't cure the disease and can have significant side effects. A key pathological hallmark of PD is the abnormal accumulation and aggregation of alpha-synuclein (α-syn), which is believed to drive neuronal death. Therefore, targeting α-syn and its downstream effects is a critical area of research for developing effective PD therapies. This paper explores whether a traditional Chinese medicine formula, CFR, can mitigate the neurotoxic effects of α-syn.

Methods

The researchers employed a multi-pronged approach using both in vivo (animal) and in vitro (cell culture) models of PD.

  • In Vivo Model: They created a PD model in male Sprague-Dawley (SD) rats by injecting adeno-associated virus (AAV) carrying the α-syn gene into the substantia nigra. These rats were then treated with CFR for six weeks.
  • In Vitro Model: Human neuroblastoma SK-N-SH cells were used. These cells were first transfected with α-syn plasmids and then exposed to hydrogen peroxide (H₂O₂) to induce cellular injury. Subsequently, these cells were treated with CFR for 48 hours.

To assess the effects of CFR, a battery of assays was performed:

  • Behavioral Assessment (Rats): The apomorphine-induced rotation test was used to measure motor deficits in the rat models.
  • Cell Viability Assay (Cells): The CCK8 assay was employed to quantify the survival rate of SK-N-SH cells.
  • Apoptosis Detection: The TUNEL assay was used in both rat brain tissues and cell cultures to identify and quantify apoptotic cells.
  • Protein Expression Analysis: Immunofluorescence staining was used to visualize α-syn expression in cells, while Western blot analysis was performed on both rat brain tissues and cell lysates to measure the protein levels of α-syn, GSK-3β, phosphorylated GSK-3β (at Ser9 and Tyr216), and β-catenin.

Datasets

Not discussed in the paper. The study utilized established cell lines (SK-N-SH) and animal models (SD rats) and generated its own experimental data.

Key Insights and Ideas

  • Targeting α-syn Toxicity: The study strongly suggests that CFR can counteract the neurotoxic effects of α-syn, a central player in PD pathogenesis. This opens avenues for developing therapies that directly address the root cause of neuronal damage.
  • Dual In Vivo and In Vitro Validation: Demonstrating protective effects in both animal models and cell cultures provides robust evidence for CFR's potential therapeutic value.
  • GSK-3β/β-catenin Pathway Modulation: The findings highlight the involvement of the GSK-3β/β-catenin signaling pathway in α-syn-induced neurotoxicity and suggest that CFR's protective effects are mediated, at least in part, through its regulation of this pathway. Specifically, CFR appears to inhibit the pro-apoptotic GSK-3β activity (indicated by increased P-GSK-3β (Ser9) and decreased P-GSK-3β (Tyr216)) and promote the pro-survival β-catenin.
  • Traditional Medicine's Potential: This research underscores the value of exploring traditional medicine formulations for modern therapeutic applications, particularly in complex diseases like PD.

Key Results

  • Behavioral Improvement in Rats: CFR treatment significantly reduced the abnormal rotation behavior in α-syn-induced PD model rats, indicating an improvement in motor function.
  • Enhanced Cell Viability: In the in vitro model, CFR significantly improved the viability of SK-N-SH cells that were stressed by H₂O₂ and α-syn.
  • Reduced Apoptosis: TUNEL assays showed that CFR significantly decreased the number of apoptotic cells in both the substantia nigra and striatum of PD model rats, as well as in the treated SK-N-SH cells.
  • Inhibition of α-syn Overexpression: Both in vivo and in vitro experiments showed that CFR treatment reduced the elevated levels of α-syn.
  • Modulation of Signaling Pathways: Western blot analysis revealed that CFR administration normalized the expression of GSK-3β, P-GSK-3β (Ser9), P-GSK-3β (Tyr216), and β-catenin in both PD rat brains and treated cells, suggesting a protective role in this critical signaling cascade.

Limitations and Future Work

  • Mechanism Elucidation: While the study points to the GSK-3β/β-catenin pathway, further in-depth investigation is needed to fully elucidate the precise molecular mechanisms by which CFR exerts its neuroprotective effects.
  • Compound Identification: The paper describes CFR as a "compound formula" composed of five herbs. Identifying the specific active compounds within CFR responsible for the observed effects would be a crucial next step for drug development.
  • Clinical Translation: The study was conducted in animal and cell models. Future work should focus on preclinical and clinical trials to assess the safety and efficacy of CFR in human PD patients.
  • Long-Term Effects: The in vivo study involved a 6-week treatment period. Investigating the long-term effects and potential for sustained neuroprotection would be valuable.

Summary updated

Abstract

The present study aimed to investigate the protective effect of compound formula Rehmannia (CFR) against the development of Parkinson's disease (PD). After the <i>in vivo</i> and <i>in vitro</i> models of PD were established with overexpression <i>α</i>-syn induced, CFR was administrated into the PD model rats for 6 weeks or SK-N-SH cells with coincubation for 48 h. Apomorphine-induced rotation test, CCK8 assay, TUNEL assay, immunofluorescence staining, and western blot assay were performed to evaluate the behavioral changes, cell viability, cell apoptosis, <i>α</i>-syn, GSK-3<i>β</i>, P-GSK-3<i>β</i> (Ser9), P-GSK-3<i>β</i> (Tyr216), and <i>β</i>-catenin expression in PD rats or SK-N-SH cells. PD rat behavior results showed that the rotation numbers were significantly decreased in the CFR treatment group comparing with the AAV-<i>α</i>-syn PD model group. The cell viability suppressed by H<sub>2</sub>O<sub>2</sub> and <i>α</i>-syn in SK-N-SH model cells was also significantly improved with CFR administration. Cell apoptosis and <i>α</i>-syn overexpression observed in PD rats and SK-N-SH cells were also inhibited by CFR treatment. Furthermore, the protein expression of <i>α</i>-syn, GSK-3<i>β</i>, P-GSK-3<i>β</i> (Ser9), P-GSK-3<i>β</i> (Tyr216), and <i>β</i>-catenin in <i>in vivo</i> and <i>in vitro</i> was also significantly regulated by CFR. The present study suggested that CFR may be considered as a potential neuroprotective agent against PD, and this application will require further investigation.
BibTeX
@inproceedings{long2020protective,
  author = {Teng Long and Minchun Yang and Xiaoqing Jin and Qian Lu and Weijia Yang and Xuanxuan Ren and Qing Qu},
  title = {{Protective Effect of Compound Formula Rehmannia against Neurotoxicity and Apoptosis Induced by <i>α</i>‐Syn in <i>In Vivo</i> and <i>In Vitro</i> Models of Parkinson’s Disease}},
  booktitle = {Evidence-based},
  year = {2020},
  doi = {10.1155/2020/5201912},
}
Figure